Wei Guo

Wei Guo

Auto-generated profile, based on publicly available information

Wei Guo

The Affiliated Suqian Hospital of Xuzhou Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
WLWei Li
Wei Li
WGWei Guo
Wei Guo
HCHongdou Chen
Hongdou Chen
WLWei Lu
Wei Lu
SYShule Yu
Shule Yu
QYQingqing Yang
Qingqing Yang
The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China. Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China. The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption. The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.

1 February 2025 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
WGWei Guo
Wei Guo
HZHan Zhang
Han Zhang
YLYan Quan Lin
Yan Quan Lin
GWGang Wu
Gang Wu
WLWei Li
Wei Li
HCHongdou Chen
Hongdou Chen
Objective: To analyze and predict the dynamic influence trends and degrees caused by various factors that may affect the expansion of the hospital pharmacist team in China. Methods: Time series data including the number of hospital visits in all hospitals in China, the total number of pharmacists, per capita health expenditure, and per capita GDP from 2002 to 2022 were collected at the national level. A vector autoregressive (VAR) model was constructed, and methods such as the Granger causality test, impulse response analysis, and variance decomposition were employed to explore the influence process and direction of various influencing factors on the number of pharmacists in China. Results: The Augmented Dickey-Fuller (ADF) test indicates the first-order difference series of the time series is stationary (P< 0.05). The model stability test shows the modulus of all specific root reciprocals falls within the unit circle, indicating model stability and credible results. The cointegration test reveals a cointegration relationship among the number of hospital visits, per capita health expenditure, per capita GDP, and the number of pharmacists (P< 0.05). The Granger causality test indicates a unidirectional Granger causality relationship between the number of hospital visits, per capita health expenditure, and the number of pharmacists. The impulse response function indicates that the number of pharmacists shows an upward trend after being impacted by one unit of the number of hospital visits and per capita GDP, while the positive impact of per capita health expenditure on the number of pharmacists turns into a negative impact in the third stage. Variance decomposition shows that the contribution rate of the number of hospital visits to the number of pharmacists is 12%, the contribution rate of per capita health expenditure to the number of pharmacists is 57%, and the contribution rate of per capita GDP to the number of pharmacists is 80%. Conclusion: The number of hospital visits, per capita health expenditures, and per capita GDP all positively contribute to the development of the pharmacist workforce. Per capita health expenditures lead to an increase in the number of pharmacists in the short term. Among the selected indicators, the primary drivers of pharmacist workforce development are per capita health expenditures and per capita GDP. Hospital visits have a relatively minor contribution to the growth in the number of pharmacists.